reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
== P == Pasteurella Pasteurella canis Pasteurella multocida Peptostreptococcus anaerobius Photobacterium damselae subsp. damselae (previously Vibrio damsela) Porphyromonas gingivalis Prevotella melaninogenica (formerly Bacteroides melaninogenicus) Proteus Proteus mirabilis Proteus penneri Proteus vulgaris Pseudomonas aeruginosa
==== Aerosol mass spectrometer ==== The Aerodyne AMS provides real-time aerosol mass spectrometry analysis of size-resolved mass concentration of non-refractory components (Ex. organics, sulfate, nitrate, and ammonium). The term non-refractory is assigned to species that evaporate rapidly at 600 °C under vacuum conditions (e.g. organic matter, NH4NO3 and (NH4)2SO4. The schematic of a typical AMS is shown in the figure to the right. The Aerodyne AMS is made up of three sections; The aerosol inlet, the particle sizing chamber, and the particle detection chamber. The aerosol inlet has a flow limiting orifice entrance that is around 100 um in diameter. Once in the chamber the sample goes through aerodynamic focusing lens system, which consist of several orifice lenses that are mount in sequence of decreasing inner diameter. The lens focuses the particles into a narrow particle beam. The beam now travels through the particle sizing chamber, where the particle aerodynamic diameter is measured. The particle sizing chamber is made up of a flight tube maintained at (~ 10−5 torr). The entrance of the flight tube is a mechanical chopper that's used to modulate the particle beam; then using both the fixed length of the tube and the time-resolved detection of the arrival at the end, the particles' velocities can be determined. Using the velocity, the particle's diameter is obtained. As the particle beam exits the flight tube, it enters the particle composition detection chamber. In this section, the particles collide with a heated tungsten element (~600 °C).
This makes it a highly effective treatment for negative and cognitive symptoms of schizophrenia since 5HT2A antagonism increases dopamine release in the mesocortical pathway which is hypoactive in those with schizophrenia. Interestingly, lumateperone indirectly augments glutamatergic neurotransmission through its activity at D1 receptors, which causes phosphorylation of GluN2B subunits of NMDA receptors in the mesolimbic pathway. This is significant since NMDA receptor hypofunction, reduced D1 binding, and glutamatergic abnormalities have been implicated in contributing to the cognitive and negative symptoms of schizophrenia. It has also been identified as a potent vesicular monoamine transporter 2 (VMAT2) inhibitor (IC50Tooltip half-maximal inhibitory concentration = 62 nM).
Sources: en.wikipedia.org
=== Affinity-based Screening === Screening is used to find the apparent affinities of heterologous proteins displayed on the bacterial cell surface for target proteins. This method is usually combined with FACS, and the addition of a non-fluorescent target protein competitor is beneficial to obtaining more accurate binding affinities. Adding a competitor reduces the chance of target proteins rebinding, which would render the binding affinity less accurate.
== Methods == Bisulfite sequencing applies routine sequencing methods on bisulfite-treated genomic DNA to determine methylation status at CpG dinucleotides. Other non-sequencing strategies are also employed to interrogate the methylation at specific loci or at a genome-wide level. All strategies assume that bisulfite-induced conversion of unmethylated cytosines to uracil is complete, and this serves as the basis of all subsequent techniques. Ideally, the method used would determine the methylation status separately for each allele. Alternative methods to bisulfite sequencing include Combined Bisulphite Restriction Analysis and methylated DNA immunoprecipitation (MeDIP). Methodologies to analyze bisulfite-treated DNA are continuously being developed. To summarize these rapidly evolving methodologies, numerous review articles have been written. The methodologies can be generally divided into strategies based on methylation-specific PCR (MSP) (Figure 4), and strategies employing polymerase chain reaction (PCR) performed under non-methylation-specific conditions (Figure 3). Microarray-based methods use PCR based on non-methylation-specific conditions also.
== Further reading == Altschul, SF (1991). "Amino acid substitution matrices from an information theoretic perspective". Journal of Molecular Biology. 219 (3): 555–65. doi:10.1016/0022-2836(91)90193-A. PMC 7130686. PMID 2051488. Dayhoff, M. O.; Schwartz, R. M.; Orcutt, B. C. (1978). "A model of evolutionary change in proteins". Atlas of Protein Sequence and Structure. 5 (3): 345–352. Eddy, SR (2004). "Where did the BLOSUM62 alignment score matrix come from?". Nature Biotechnology. 22 (8): 1035–6. doi:10.1038/nbt0804-1035. PMID 15286655. S2CID 205269887. Henikoff, S; Henikoff, JG (1992). "Amino acid substitution matrices from protein blocks". Proceedings of the National Academy of Sciences of the United States of America. 89 (22): 10915–9. Bibcode:1992PNAS...8910915H. doi:10.1073/pnas.89.22.10915. PMC 50453. PMID 1438297.
Sources: en.wikipedia.org
In 1769, William Cullen called attention to diabetic urine that was "insipid" in taste:I myself, indeed, think I have met with one instance of diabetes in which the urine was perfectly insipid; and it would seem that a like observation had occurred to Dr. Martin Lister. I am persuaded, however, that such instances are very rare; and that the other is much more common and perhaps the almost universal occurrence. I judge therefore, that the presence of such a saccharine matter may be considered as the principal circumstance in idiopathic diabetes.In 1788, Thomas Cawley published a case study in the London Medical Journal based on an autopsy of a diabetic patient. He suggested a link between the pancreas and diabetes after observing stones and signs of tissue damage in the patient's pancreas. The significance of this discovery went unappreciated for another hundred years. In 1794, Johann Peter Frank of the University of Pavia found that his patients were characterized by "long continued abnormally increased secretion of non-saccharine urine which is not caused by a diseased condition of the kidneys". He introduced the term insipidus, derived from the Latin ('tasteless'). Frank is often credited as the first physician to describe clinical differences between diabetes mellitus and diabetes insipidus. This claim, however, warrants further examination given prior instances of comparable description (e.g. those by William Cullen). It has been noted that 1792 seems to be the year when "unequivocal" diabetes insipidus was first described in the medical literature.
== D == DAIDS – data safety and monitoring board (DSMB) – deletion – dementia – demyelination – dendrite – dendritic cells – deoxyribonucleic acid (DNA) – Department of Health and Human Services (DHHS/HHS or DHHS) – desensitization – diabetes mellitus (DM) – diagnosis – diarrhea – diplopia – dissemination – division of acquired immunodeficiency syndrome (DAIDS) – DNA – dose-ranging study – dose-response relationship – double-blind study – drug resistance – drug-drug interaction – DSMB – Duffy antigen system – dysplasia – dyspnea
=== Environmental and health concerns === Fluoroalkanes are generally inert and non-toxic. Fluoroalkanes are not ozone depleting, as they contain no chlorine or bromine atoms, and they are sometimes used as replacements for ozone-depleting chemicals. The term fluorocarbon is used rather loosely to include any chemical containing fluorine and carbon, including chlorofluorocarbons, which are ozone depleting. Perfluoroalkanes used in medical procedures are rapidly excreted from the body, primarily via expiration with the rate of excretion as a function of the vapour pressure; the half-life for octafluoropropane is less than 2 minutes, compared to about a week for perfluorodecalin.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.